10/ 030,301

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	Jun 03	New e-mail delivery for search results now available
NEWS 4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 7	Sep 03	JAPIO has been reloaded and enhanced
NEWS 8	Sep 16	Experimental properties added to the REGISTRY file
NEWS 9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 11	Oct 24	BEILSTEIN adds new search fields
NEWS 12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 13	Nov 18	DKILIT has been renamed APOLLIT
NEWS 14	Nov 25	More calculated properties added to REGISTRY
NEWS 15	Dec 04	CSA files on STN
NEWS 16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 17	Dec 17	TOXCENTER enhanced with additional content
NEWS 18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS 20	Feb 13	CANCERLIT is no longer being updated
NEWS 21	Feb 24	METADEX enhancements
NEWS 22	Feb 24	PCTGEN now available on STN
NEWS 23	Feb 24	TEMA now available on STN
NEWS 24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS 25	Feb 26	PCTFULL now contains images
NEWS 26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 27	Mar 20	EVENTLINE will be removed from STN
NEWS 28	Mar 24	PATDPAFULL now available on STN
NEWS 29	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS 30	Apr 11	Display formats in DGENE enhanced
NEWS 31	Apr 14	MEDLINE Reload
NEWS 32	Apr 17	Polymer searching in REGISTRY enhanced
NEWS 33	Apr 21	Indexing from 1947 to 1956 being added to records in CA/CAPLUS
NEWS 34	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS 35	Apr 28	RDISCLOSURE now available on STN
NEWS 36	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS 37	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS 38	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 39	May 16	CHEMREACT will be removed from STN
NEWS 40	May 19	Simultaneous left and right truncation added to WSCA
NEWS 41	May 19	RAPRA enhanced with new search field, simultaneous left and right truncation

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),

10/ 030,301

```
                AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
 NEWS HOURS     STN Operating Hours Plus Help Desk Availability
 NEWS INTER     General Internet Information
 NEWS LOGIN     Welcome Banner and News Items
 NEWS PHONE     Direct Dial and Telecommunication Network Access to STN
 NEWS WWW       CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:16:34 ON 05 JUN 2003

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 15:16:44 ON 05 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    4 JUN 2003  HIGHEST RN 525536-93-0
DICTIONARY FILE UPDATES:   4 JUN 2003  HIGHEST RN 525536-93-0

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 10030301.str

L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
```

10/ 030,301

Hy

N

N

G1

N N

G1 C,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 15:17:02 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     156 TO ITERATE

100.0% PROCESSED     156 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          2371 TO     3869
PROJECTED ANSWERS:                0 TO        0

L2             0 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 15:17:09 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    2997 TO ITERATE

100.0% PROCESSED    2997 ITERATIONS                               10 ANSWERS
SEARCH TIME: 00.00.01

L3            10 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     148.15     148.36

FILE 'CAPLUS' ENTERED AT 15:17:29 ON 05 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 5 Jun 2003 VOL 138 ISS 23
FILE LAST UPDATED: 4 Jun 2003 (20030604/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 2 L3

=> d l4 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 2 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:171900 CAPLUS
DOCUMENT NUMBER: 136:216764
TITLE: Process for the preparation of 3-(6-piperidinylpurin-9-yl)propionates as vitronectin receptor antagonists
INVENTOR(S): Peyman, Anuschirwan; Schubert, Gerrit
PATENT ASSIGNEE(S): Aventis Pharma Deutschland Gmbh, Germany
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002018384	A1	20020307	WO 2001-EP9985	20010829
W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CO, CR, CU, CZ, DM, DZ, EC, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PH, PL, RO, SG, SI, SK, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10042655	A1	20020314	DE 2000-10042655	20000831
AU 2001093791	A5	20020313	AU 2001-93791	20010829
EP 1315728	A1	20030604	EP 2001-974220	20010829
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: DE 2000-10042655 A 20000831
WO 2001-EP9985 W 20010829
OTHER SOURCE(S): CASREACT 136:216764; MARPAT 136:216764
GI



I

II

AB The present invention relates to a process for the prepn. of vitronectin receptor antagonists I [wherein R = G1 or G2; R1, R2, R3, and R4 = independently H, F, Cl, CN, (un)substituted alkyl, cycloalkyl(alkyl), or aryl(alkyl), or R6OR7, R6R6'NR7, R6COR7, R6SO2N(R9)R7, R6OCON(R9)R7, R6CON(R5)R7, R6N(R9)CON(R9)R7, R6N(R9)SO2N(R9)R7, R6SO2R7, R6SCON(R9)R7, R6N(R9)COR7, R6N(R9)SO2R7, R6N(R9)R7, or heterocyclyl; R5 = OH, (aryl)alkoxy, alkylcarbonyloxyalkoxy, or cyclo(alkyl)alkoxy; R6 and R6' = independently (un)substituted alkyl, cycloalkyl(alkyl), aryl(alkyl), or heterocyclyl; R7 = independently alkanediyl or a direct bond; R9 = H or alkyl; and stereoisomers and salts thereof] by coupling a 9-chloropurine I [R = Cl] to a 4-substituted piperidine and comprises an efficient method for the prepn. of I [R = Cl]. In contrast to prior art, the process according to the invention gives good yields in a lower no. of steps and can be used advantageously for the syntheses on a relatively large scale. For example, Et (2S)-2-(naphthalene-1-sulfonylamino)-3-aminopropionate was aminated with 4,6-dichloro-5-nitropyrimidine in THF in the presence of TEA and then reduced to the amine using SnCl2 in EtOH. Cyclocondensation with tri-Et orthoformate in N-methylpyrrolidone in the presence of EtSO3H gave the 6-chloropurine. Reaction with 7-(piperidin-4-yl)-1,2,3,4-tetrahydro-[1,8]naphthyridine in DMF and diisopropylethylamine at 70.degree.C for 3 h afforded the piperidinylpurinylpropionate II.

IT **402501-87-5P**, Ethyl (2S)-2-(naphthalene-1-sulfonylamino)-3-[6-[4-(5,6,7,8-tetrahydro[1,8]naphthyridin-2-yl)piperidin-1-yl]purin-9-yl]propionate
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(target compd.; process for prepn. purinylpropionate vitronectin receptor antagonists starting from nitropyrimidines and aminopropionates)

RN 402501-87-5 CAPLUS

CN 9H-Purine-9-propanoic acid, .alpha.-[(1-naphthalenylsulfonyl)amino]-6-[4-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)-1-piperidinyl]-, ethyl ester, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR TH1S RECORD. ALL CITAT1ONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:10662 CAPLUS
DOCUMENT NUMBER: 134:71600
TITLE: Naphthyridine derivatives, processes for their preparation, their use as vitronectin receptor antagonists and inhibitors of cell adhesion, and pharmaceutical compositions comprising them
1NVENTOR(S): Peyman, Anuschirwan; Scheunemann, Karl-Heinz; Gourvest, Jean-Francois; Ruxer, Jean-Marie; Gadek, Thomas R.
PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany; Genentech, Inc.
SOURCE: Eur. Pat. Appl., 36 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1065207	A1	20010103	EP 1999-112636	19990702
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, 1E, SI, LT, LV, FI, RO				
WO 2001002398	A1	20010111	WO 2000-EP5920	20000626
W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, 1D, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT,				

LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA,
US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

BR 2000012129	A	20020507	BR 2000-12129	20000626	
EP 1210348	A1	20020605	EP 2000-945825	20000626	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL					
JP 2003503496	T2	20030128	JP 2001-507835	20000626	
NZ 516058	A	20030131	NZ 2000-516058	20000626	
EE 200100711	A	20030415	EE 2001-711	20000626	
BG 106257	A	20021031	BG 2001-106257	20011220	
NO 2001006404	A	20020301	NO 2001-6404	20011228	
PRIORITY APPLN. INFO.:			EP 1999-112636 A	19990702	
			WO 2000-EP5920 W	20000626	

OTHER SOURCE(S): MARPAT 134:71600
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to compds. I. G is -(CR1R2)n-A-(CR1R2)m-(CR1R3)i-(CR1R2)q-R4. A is a direct bond, -C(O)NR5-, -NR5C(O)-, -C(O)-, -NR5-, -O-, -S-, -S(O)-, -S(O)2-, (C2-C4)alkynediyl, (C2-C4)alkenediyl, (C5-C14)arylene where in the arylene residue 1-5 ring C atoms can be replaced by heteroatoms N, O and S, or a divalent residue of a 3-7-membered satd. or unsatd. ring which can contain 1-2 ring heteroatoms N, S and O and which can be monosubstituted or disubstituted by residues :O, :S and R3. B is (C1-C18)alkyl, (C3-C14)cycloalkyl, (C3-C14)cycloalkyl(C1-C8)alkyl, (C5-C14)aryl, (C5-C14)aryl(C1-C8)alkyl, (C5-C14)heteroaryl, (C5-C14)heteroaryl(C1-C8)alkyl, F, Cl, Br, OH, CN, CF3, NO2, CO2H, (C1-C6)alkoxy, (C1-C6)alkoxy(C1-C6)alkyl, (C1-C6)alkoxycarbonyl, (C1-C6)alkylcarbonyl, (C5-C14)arylcarbonyl, (C1-C6)alkylaminocarbonyl, (C1-C6)alkoxy(C1-C6)alkoxy, (C5-C14)aryl(C1-C8)alkylcarbonyl, (C1-C6)alkanoylamino, (C1-C6)alkylsulfonylamino, (C5-C14)arylsulfonylamino, (C1-C6)alkylamino, di((C1-C6)alkyl)amino, (C1-C6)alkylsulfonyl, aminosulfonyl, (C5-C14)arylsulfonyl, (C5-C14)aryl(C1-C8)alkylsulfonyl, (C5-C14)aryl or (C5-C14)heteroaryl, where all residues B are independent of one another and can be identical or different. X is H, NR6R6', F, Cl, Br, OR6, SR6, hydroxy(C1-C6)alkyl-NH-, (hydroxy(C1-C6)alkyl)2N-, amino(C1-C6)alkyl-NH-, (amino(C1-C6)alkyl)2N-, hydroxy(C1-C6)alkyl-O-, hydroxy(C1-C6)alkyl-S- or -NH-C(O)-R6. Y is R5, F, Cl, Br, CN, NR6R6', OR6, SR6 or hydroxy(C1-C6)alkyl-NH-. Z is N or CH. R1 and R2 are H, F, Cl, CN, NO2, (C1-C10)alkyl, (C3-C14)cycloalkyl, (C3-C14)cycloalkyl(C1-C8)alkyl, (C5-C14)aryl, (C5-C14)aryl(C1-C8)alkyl, (C5-C14)heteroaryl, (C5-C14)heteroaryl(C1-C8)alkyl, R6-O-R7, R6-S(O)p-R7, R6S(O)2NHR7, R6OC(O)NHR7 or R6R6'N-R7, where all residues R1 and R2 are independent of one another and can be identical or different. R3 is H, F, Cl, CN, NO2, (C1-C18)alkyl, (C3-C14)cycloalkyl, (C3-C14)cycloalkyl(C1-C8)alkyl, (C5-C14)aryl, (C5-C14)aryl(C1-C8)alkyl, (C5-C14)heteroaryl, (C5-C14)heteroaryl(C1-C8)alkyl, R6-O-R7, R6R6'N-R7, R6C(O)-O-R7, R6C(O)R7, R6OC(O)R7, R6N(R6')C(O)OR7, R6S(O)pN(R5)R7, R6OC(O)N(R5)R7, R6C(O)N(R5)R7, R6N(R6')C(O)N(R5)R7, R6N(R6')S(O)pN(R5)R7, R6S(O)pR7, R6SC(O)N(R5)R7, R6N(R6')C(O)R7 or R6N(R6')S(O)pR7, where alkyl can be monounsatd. or polyunsatd. and where alkyl, cycloalkyl, aryl, and heteroaryl can be monosubstituted or polysubstituted by R6, F, Cl, Br, CN, CF3, R6R6'NR7, NO2, R6OC(O)R7, R6C(O)R7, R6N(R6')C(O)R7, R6N(R6')S(O)pR7 or R6-O-R7, and where all residues R3 are independent of one another and can be identical or different. R4 is -C(O)R8, -C(S)R8, -S(O)pR8, -P(O)R8R8' or a residue

of a 4-8-membered satd. or unsatd. heterocycle which contains 1-4 heteroatoms N, O and S. R5 is H, (C1-C10)alkyl, (C3-C14)cycloalkyl, (C3-C14)cycloalkyl(C1-C8)alkyl, (C5-C14)aryl or (C5-C14)aryl(C1-C8)alkyl, where all residues R5 are independent of one another and can be identical or different. R6 and R6' are H, (C1-C18)alkyl, (C3-C14)cycloalkyl, (C3-C14)cycloalkyl(C1-C8)alkyl, (C5-C14)aryl, (C5-C14)aryl(C1-C8)alkyl, (C5-C14)heteroaryl or (C5-C14)heteroaryl(C1-C8)alkyl where aryl, heteroaryl, cycloalkyl and alkyl can be substituted 1-3 times by identical or different substituents F, Cl, Br, CN, CF3, NO2, CO2H, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkoxy(C1-C6)alkyl, (C1-C6)alkoxycarbonyl, (C1-C6)alkylcarbonyl, (C1-C6)alkylaminocarbonyl, (C1-C6)alkoxy(C1-C6)alkoxy, (C5-C14)arylcarbonyl, (C5-C14)aryl(C1-C8)alkylcarbonyl, (C1-C6)alkanoylamino, (C5-C14)arylsulfonylamino, (C1-C6)alkylsulfonylamino, (C1-C6)alkylamino, di((C1-C6)alkyl)amino, (C1-C6)alkylsulfonyl, (C1-C6)alkylaminosulfonyl, (C5-C14)arylaminosulfonyl, (C5-C14)aryl(C1-C8)alkylaminosulfonyl, (C5-C14)arylsulfonyl, (C5-C14)aryl(C1-C8)alkylsulfonyl, (C5-C14)aryl and (C5-C14)heteroaryl, and where all residues R6 and R6' are independent of one another and can be identical or different. R7 is (C1-C4)alkanediyl or a direct bond, where all residues R7 are independent of one another and can be identical or different. R8 and R8' are OH, (C1-C8)alkoxy, (C5-C14)aryl(C1-C8)alkoxy, (C5-C14)aryloxy, (C1-C8)alkylcarbonyloxy(C1-C4)alkoxy, (C5-C14)aryl(C1-C8)alkylcarbonyloxy(C1-C8)alkoxy, NR6R6', (di((C1-C8)alkyl) amino)carbonylmethyloxy, (di((C5-C14)aryl(C1-C8)alkyl)amino)carbonylmethyloxy, (C5-C14)arylamino, the residue of an amino acid, N-((C1-C4)alkyl)piperidin-4-yloxy, 2-methylsulfonylethoxy, 1,3-thiazol-2-ylmethyloxy, 3-pyridylmethyloxy, 2-(di((C1-C4)alkyl)amino)ethoxy or the residue Q-(CH3)3N+-CH2-CH2-O- in which Q- is a physiol. tolerable anion, where all residues R8 and R8' are independent of one another and can be identical or different. N is 0-5; m is 0-5; i is 0-1; q is 0-2; r is 0-2; s is 0-3; t is 0-8; p is 0-2, where all nos. p are independent of one another and can be identical or different. The claimed compds. also include stereoisomeric forms and mixts. thereof in all ratios, and their physiol. tolerable salts and their prodrugs; where, instead of the purine structure shown I, also a 3-deazapurine structure, a 7-deazapurine structure or a 7-deaza-8-azapurine structure can be present. I are valuable pharmacol. active compds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and are suitable for the therapy and prophylaxis of illnesses which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for inhibiting bone resorption by osteoclasts and thus for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or proliferation of cells of the vascular smooth musculature. The invention furthermore relates to processes for the prepn. of I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compns. comprising them. The process of prepn. comprises reacting II (L1 = leaving group) with III or IV; B, G, X, Y, r, s and t are defined as above but wherein functional groups can also be present in the form of precursor groups or in protected form. For example, (2S)-2-benzyloxycarbonylamino-3-(6-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl)purin-9-yl)propionic acid tert-Bu ester could be made from 7-(piperidin-4-yl)-1,2,3,4-tetrahydro-1,8-naphthyridine and (S)-2-benzyloxycarbonylamino-3-(6-chloropurin-9-yl)propionic acid tert-Bu ester in DMF in the presence of NEtiPr2; the ester was then hydrolyzed by CF3CO2H to give the desired compd.

IT **315240-30-3P**, (2S)-2-Benzyloxycarbonylamino-3-(6-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl)purin-9-yl)propionic acid tert-butyl ester **315240-32-5P**, (2S)-2-Amino-3-(6-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl)purin-9-yl)propionic acid tert-butyl ester **315240-34-7P**, (2S)-2-Benzenesulfonylamino-3-(6-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl)purin-9-

yl)propionic acid tert-butyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; naphthyridine derivs., processes for prepn., uses as vitronectin receptor antagonists and inhibitors of cell adhesion, and pharmaceutical compns. comprising them)

RN 315240-30-3 CAPLUS
CN 9H-Purine-9-propanoic acid, .alpha.-[[(phenylmethoxy)carbonyl]amino]-6-[4-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)-1-piperidinyl]-, 1,1-dimethylethyl ester, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 315240-32-5 CAPLUS
CN 9H-Purine-9-propanoic acid, .alpha.-amino-6-[4-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)-1-piperidinyl]-, 1,1-dimethylethyl ester, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 315240-34-7 CAPLUS
CN 9H-Purine-9-propanoic acid, .alpha.-[(phenylsulfonyl)amino]-6-[4-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)-1-piperidinyl]-, 1,1-dimethylethyl

10/ 030,301

ester, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **315240-14-3P**, (2S)-2-Benzyloxycarbonylamino-3-(6-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl)purin-9-yl)propionic acid **315240-16-5P**, (2S)-2-Benzenesulfonylamino-3-(6-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl)purin-9-yl)propionic acid **315240-18-7P**, (2S)-2-(4-Chlorobenzenesulfonylamino)-3-(6-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl)purin-9-yl)propionic acid **315240-20-1P**, (2S)-2-(Naphthalene-1-sulfonylamino)-3-(6-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl)purin-9-yl)propionic acid **315240-22-3P**, (2S)-3-(6-(4-(5,6,7,8-Tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl)purin-9-yl)-2-(4-trifluoromethylbenzenesulfonylamino)propionic acid **315240-24-5P**, (2S)-2-(Butane-1-sulfonylamino)-3-(6-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl)purin-9-yl)propionic acid
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(naphthyridine derivs., processes for prepn., uses as vitronectin receptor antagonists and inhibitors of cell adhesion, and pharmaceutical compns. comprising them)

RN 315240-14-3 CAPLUS

CN 9H-Purine-9-propanoic acid, .alpha.-[[(phenylmethoxy)carbonyl]amino]-6-[4-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)-1-piperidinyl]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 315240 16 5 CAPLUS
CN 9H-Purine-9-propanoic acid, .alpha.-[(phenylsulfonyl)amino]-6-[4-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)-1-piperidinyl]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 315240-18-7 CAPLUS
CN 9H-Purine-9-propanoic acid, .alpha.-[[(4-chlorophenyl)sulfonyl]amino]-6-[4-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)-1-piperidinyl]-, (.alpha.S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 315240-20-1 CAPLUS
CN 9H-Purine-9-propanoic acid, .alpha.-[(1-naphthalenylsulfonyl)amino]-6-[4-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)-1-piperidinyl]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 315240-22-3 CAPLUS
CN 9H-Purine-9-propanoic acid, 6-[4-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)-1-piperidinyl]-.alpha.-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/ 030,301



RN 315240-24-5 CAPLUS
CN 9H-Purine-9-propanoic acid, .alpha.-[(butylsulfonyl)amino]-6-[4-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)-1-piperidinyl]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 15:16:34 ON 05 JUN 2003)

FILE 'REGISTRY' ENTERED AT 15:16:44 ON 05 JUN 2003
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 10 S L1 FUL

FILE 'CAPLUS' ENTERED AT 15:17:29 ON 05 JUN 2003
L4 2 S L3

10/ 030,301

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	9.49	157.85

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.30	-1.30

STN INTERNATIONAL LOGOFF AT 15:18:02 ON 05 JUN 2003